What is HC Wainwright’s Estimate for LifeMD Q1 Earnings?

LifeMD, Inc. (NASDAQ:LFMD) – Equities research analysts at HC Wainwright lifted their Q1 2026 earnings per share (EPS) estimates for LifeMD in a report released on Wednesday, March 11th. HC Wainwright analyst Y. Chen now forecasts that the company will earn ($0.04) per share for the quarter, up from their prior forecast of ($0.31). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for LifeMD’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for LifeMD’s Q2 2026 earnings at $0.06 EPS, Q3 2026 earnings at $0.12 EPS, Q4 2026 earnings at $0.18 EPS and FY2026 earnings at $0.33 EPS.

LifeMD (NASDAQ:LFMD) last issued its quarterly earnings results on Monday, March 9th. The company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.03). LifeMD had a negative return on equity of 83.93% and a net margin of 6.58%.The firm had revenue of $46.87 million for the quarter, compared to the consensus estimate of $48.57 million.

Several other analysts also recently commented on the stock. B. Riley Financial decreased their price objective on shares of LifeMD from $12.00 to $10.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. BTIG Research reiterated a “buy” rating and issued a $10.00 price target on shares of LifeMD in a research note on Tuesday, March 10th. Wall Street Zen raised LifeMD from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings restated a “sell (e+)” rating on shares of LifeMD in a research report on Monday, December 29th. Finally, KeyCorp dropped their price objective on LifeMD from $12.00 to $8.00 and set an “overweight” rating for the company in a research note on Wednesday, November 19th. Six equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $8.86.

LifeMD Trading Up 1.3%

Shares of LifeMD stock opened at $3.98 on Friday. The business’s 50-day moving average price is $3.33 and its 200-day moving average price is $4.53. The firm has a market capitalization of $190.92 million, a PE ratio of 15.31 and a beta of 1.92. LifeMD has a 12 month low of $2.56 and a 12 month high of $15.84.

Hedge Funds Weigh In On LifeMD

Several large investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd bought a new position in LifeMD during the fourth quarter valued at $36,000. Magnus Financial Group LLC purchased a new position in shares of LifeMD during the 4th quarter worth about $41,000. Jain Global LLC purchased a new position in shares of LifeMD during the 4th quarter worth about $45,000. Quarry LP bought a new position in LifeMD during the 3rd quarter valued at about $52,000. Finally, Tower Research Capital LLC TRC grew its holdings in LifeMD by 110.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,674 shares of the company’s stock valued at $64,000 after purchasing an additional 2,452 shares during the last quarter. Institutional investors own 35.52% of the company’s stock.

About LifeMD

LifeMD (NASDAQ: LFMD) is a U.S.-based telehealth company that delivers on-demand, membership-based virtual healthcare services. Through its digital platform and mobile applications, LifeMD connects patients with board-certified healthcare providers for diagnosis, treatment and ongoing management of a range of acute and chronic conditions. The company’s core offering centers on personalized care plans supported by prescription fulfillment, lab testing and prescription delivery services.

LifeMD’s service portfolio spans several specialty areas, including men’s health, hormonal therapy, weight management and primary care.